Literature DB >> 23681799

C282Y polymorphism in the HFE gene is associated with risk of breast cancer.

Xiaoyan Liu1, Chunlei Lv, Xiaorong Luan, Ming Lv.   

Abstract

The C282Y and H63D polymorphisms in the HFE gene have been implicated in susceptibility of breast cancer, but a number of studies have reported inconclusive results. The aim of this study is to investigate the association between the C282Y and H63D polymorphisms in the HFE gene and breast cancer risk by meta-analysis. We searched PubMed and Embase databases, covering all related studies until March 2, 2013. Statistical analysis was performed using STATA 10.0. A total of 7 studies including 1,720 cases and 18,296 controls for HFE C282Y polymorphism and 5 studies including 942 cases and 1,571 controls for HFE H63D polymorphism were included in the meta-analysis. The results showed that HFE C282Y polymorphism was significantly associated with increased risk of breast cancer under homozygotes vs. wild-type model (OR = 2.06, 95%CI = 1.19-3.58) and recessive model (OR = 1.98, 95%CI = 1.14-3.44) but not under heterozygotes vs. wild-type model (OR = 0.97, 95%CI = 0.70-1.35), dominant model (OR = 1.00, 95%CI = 0.72-1.40) and multiplicative model (OR = 1.04, 95%CI = 0.76-1.42). However, we did not find any association between HFE H63D polymorphism and breast cancer risk under all genetic models. This current meta-analysis suggested that C282Y polymorphism rather than H63D might be associated with increased risk of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23681799     DOI: 10.1007/s13277-013-0833-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  20 in total

1.  Hemochromatosis gene (HFE) mutations and cancer risk: expanding the clinical manifestations of hereditary iron overload.

Authors:  Silvia Fargion; Luca Valenti; Anna Ludovica Fracanzani
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

2.  A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.

Authors:  J N Feder; A Gnirke; W Thomas; Z Tsuchihashi; D A Ruddy; A Basava; F Dormishian; R Domingo; M C Ellis; A Fullan; L M Hinton; N L Jones; B E Kimmel; G S Kronmal; P Lauer; V K Lee; D B Loeb; F A Mapa; E McClelland; N C Meyer; G A Mintier; N Moeller; T Moore; E Morikang; C E Prass; L Quintana; S M Starnes; R C Schatzman; K J Brunke; D T Drayna; N J Risch; B R Bacon; R K Wolff
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

4.  The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation.

Authors:  A R Kallianpur; L D Hall; M Yadav; D W Byrne; T Speroff; R S Dittus; J L Haines; B W Christman; M L Summar
Journal:  Bone Marrow Transplant       Date:  2005-06       Impact factor: 5.483

5.  Frequency of hemochromatosis gene (HFE) mutations in Russian healthy women and patients with estrogen-dependent cancers.

Authors:  Tatiana V Kondrashova; Kazuo Neriishi; Sadayuki Ban; Tatiana I Ivanova; Lyudmila I Krikunova; Nataliya I Shentereva; Iya A Smirnova; Irina A Zharikova; Marina V Konova; Senjun Taira; Anatoly F Tsyb
Journal:  Biochim Biophys Acta       Date:  2005-09-23

6.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

Review 7.  The role of iron in cancer.

Authors:  E D Weinberg
Journal:  Eur J Cancer Prev       Date:  1996-02       Impact factor: 2.497

8.  HFE C282Y homozygotes are at increased risk of breast and colorectal cancer.

Authors:  Nicholas J Osborne; Lyle C Gurrin; Katrina J Allen; Clare C Constantine; Martin B Delatycki; Christine E McLaren; Dorota M Gertig; Gregory J Anderson; Melissa C Southey; John K Olynyk; Lawrie W Powell; John L Hopper; Graham G Giles; Dallas R English
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

9.  HFE H63D mutation frequency shows an increase in Turkish women with breast cancer.

Authors:  Aysen Gunel-Ozcan; Sibel Alyilmaz-Bekmez; Emine Nilufer Guler; Dicle Guc
Journal:  BMC Cancer       Date:  2006-02-19       Impact factor: 4.430

10.  HFE C282Y and H63D in adults with malignancies in a community medical oncology practice.

Authors:  James C Barton; Luigi F Bertoli; Ronald T Acton
Journal:  BMC Cancer       Date:  2004-02-10       Impact factor: 4.430

View more
  7 in total

1.  Plasma ferritin levels, HFE polymorphisms, and risk of pancreatic cancer among Chinese Han population.

Authors:  Zhiming Zhao; Chenggang Li; Minggeng Hu; Jidong Li; Rong Liu
Journal:  Tumour Biol       Date:  2014-05-06

2.  Association of the apolipoprotein E 2 allele with concurrent occurrence of endometrial hyperplasia and endometrial carcinoma.

Authors:  Tatiana I Ivanova; Ludmila I Krikunova; Nikolay I Ryabchenko; Liana S Mkrtchyan; Vera A Khorokhorina; Lyubov E Salnikova
Journal:  Oxid Med Cell Longev       Date:  2015-02-09       Impact factor: 6.543

3.  Iron depletion results in Src kinase inhibition with associated cell cycle arrest in neuroblastoma cells.

Authors:  Gamini Siriwardana; Paul A Seligman
Journal:  Physiol Rep       Date:  2015-03

4.  The risk of new-onset cancer associated with HFE C282Y and H63D mutations: evidence from 87,028 participants.

Authors:  Yang-Fan Lv; Xian Chang; Rui-Xi Hua; Guang-Ning Yan; Gang Meng; Xiao-Yu Liao; Xi Zhang; Qiao-Nan Guo
Journal:  J Cell Mol Med       Date:  2016-02-19       Impact factor: 5.310

5.  Impact of HFE variants and sex in lung cancer.

Authors:  Sang Y Lee; Vonn Walter; Junjia Zhu; Anna C Salzberg; Dajiang J Liu; James R Connor
Journal:  PLoS One       Date:  2019-12-19       Impact factor: 3.240

Review 6.  HFE gene variants, iron, and lipids: a novel connection in Alzheimer's disease.

Authors:  Fatima Ali-Rahmani; Cara-Lynne Schengrund; James R Connor
Journal:  Front Pharmacol       Date:  2014-07-08       Impact factor: 5.810

7.  Construction of Immune-Associated Nomogram for Predicting the Recurrence Survival Risk of Stage I Cervical Cancer.

Authors:  Yajuan Wang; Lejing Zhang; Bin Wang; Yuanfang Cheng
Journal:  Biomed Res Int       Date:  2021-07-09       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.